GlassScriptPhysician profile
Michael Wade Jorgensen
NPI 1558675157
$5,770.83
in general payments reported to CMS, 2019-2025
17 companies · $1,431 in 2025
The $1,431 reported for 2025 was more than what 95% of Optometrist providers received nationally (typical 2025 total: $204).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $289 · 2020: $581 · 2021: $672 · 2022: $443 · 2023: $1,148 · 2024: $1,206 · 2025: $1,431.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $3,368 · Entertainment: $418.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $3,368.00 |
| Entertainment | $417.80 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alcon Vision LLC | $1,536.99 | 2019-2025 | Precision7, Total30, Hydrus Microstent |
| Optos, INC. | $536.33 | 2021-2025 | Panoramic Ophthalmoscope, Oct Ophthalmoscope, Nfc-700 |
| Allergan, INC. | $507.72 | 2019-2022 | |
| Abbvie INC. | $453.81 | 2022-2025 | |
| Tarsus Pharmaceuticals, INC. | $433.30 | 2024-2025 | Xdemvy |
| Sun Pharmaceutical Industries INC. | $412.14 | 2020-2024 | Cequa |
| Biotissue Holdings INC. | $402.99 | 2025 | |
| Carl Zeiss Meditec USA, INC. | $279.40 | 2023 | Cirrus Hd-Oct, Clarus |
| Sight Sciences, INC. | $250.08 | 2020-2025 | Tearcare System |
| Dompe US, INC. | $243.40 | 2023-2024 | Oxervate |
| Glaukos Corporation | $181.86 | 2024 | Idose |
| Kala Pharmaceuticals, INC. | $124.46 | 2021 | |
| Coopervision INC. | $117.78 | 2024 | Clariti Contact Lens |
| Rxsight INC | $117.31 | 2022 | |
| Ivantis, INC | $72.28 | 2020 |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Harrow Eye, LLC | $72.14 | 2024-2025 | Iheezo, Flarex, Verkazia |
| Ocular Therapeutix, INC. | $28.84 | 2023 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Jorgensen listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.